Evidence map›Paper›PMID 41693511›Full record

ArticleJournal of pediatric gastroenterology and nutrition2026

Multicenter experience using tofacitinib for treatment of refractory pediatric inflammatory bowel diseases in the United States.

Denise D Young, Jennifer E Murphy, Mallory Chavannes, Jennifer L Dotson, Jeanne Tung, Erica Chang, Brad Pasternak, Erin Crawford, Nancy McGreal, Jonathan Moses and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Denise D YoungDivision of Pediatric Gastroenterology, Hepatology and Nutrition, UH Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0001-8722-6376
Jennifer E MurphyClinical Research Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Mallory ChavannesDepartment of Pediatrics, Children's Hospital Los Angeles, Division of Gastroenterology, Hepatology and Nutrition, Los Angeles, California, USA.
Jennifer L DotsonPediatric Gastroenterology, Hepatology, and Nutrition, Arkansas Children's Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Jeanne TungPediatric Gastroenterology, Hepatology and Nutrition, University of Oklahoma, Norman, Oklahoma, USA.
Erica ChangDivision of Pediatric Gastroenterology, Phoenix Children's Hospital, Phoenix, Arizona, USA.
Brad PasternakDivision of Pediatric Gastroenterology, Phoenix Children's Hospital, Phoenix, Arizona, USA.
Erin CrawfordDivision of Pediatric Gastroenterology, Hepatology and Nutrition, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Nancy McGrealDivision of Gastroenterology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA.
Jonathan MosesDivision of Pediatric Gastroenterology, Hepatology, and Nutrition, Stanford Medicine Children's Hospital, Palo Alto, California, USA.
Sandra C KimPediatric Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, Ohio, USA.

Funding

Case Western Reserve University Clinical and Translational Science Collaborative (CTSC) 4UL1TR000439Clinical Research Center of University Hospitals Cleveland Medical Center (UHCMC)None
6 · The paper itself

Abstract

objectivesTofacitinib is a selective Janus kinase (JAK-1) inhibitor approved for the treatment of ulcerative colitis (UC) in adults. Data is limited in the pediatric population. The aim of this study was to evaluate the efficacy of tofacitinib in pediatric inflammatory bowel disease (IBD). The primary aim was to assess clinical response (categorical improvement in disease activity from baseline) after induction (8-12 weeks). The secondary aims were to assess effectiveness of tofacitinib in achieving corticosteroid-free remission and biochemical response and overall safety.

methodsWe performed a retrospective multicenter study of pediatric patients with IBD at eight centers across the United States between 2018 and 2023. We collected demographic data, disease classification, prior biologic medication use, laboratory and clinical disease activity, corticosteroid use, adverse events and side effects, and surgical data.

resultsThirty-seven patients were included in this study. Eighteen patients (52.9%) achieved a clinical response within 8-12 weeks, which increased to 20 (58.8%) by 20-28 weeks. Corticosteroid-free remission was achieved by 14 patients (41.2%) by 8-12 weeks, followed by 16 patients (47.1%) at 20-28 weeks. Improvement in albumin and C-reactive protein (CRP) occurred as early as 8-12 weeks. Surgical rate was 10.5% (4/38 patients). Infection was a common adverse effect reported with the use of tofacitinib.

conclusionThis is one of the largest studies evaluating the use of tofacitinib in pediatric IBD in the United States. Our results demonstrate that tofacitinib is an effective treatment for these patients.

Indexed as

Inflammatory Bowel DiseasesPiperidinesProtein Kinase InhibitorsPyrimidinesAdolescentChildChild, PreschoolColitis, UlcerativeFemaleHumansMaleRemission InductionRetrospective StudiesTreatment OutcomeUnited StatesPiperidinesProtein Kinase InhibitorsPyrimidinestofacitinibJAK inhibitorsmall‐molecule agentsulcerative colitis

Identifiers

PMID41693511
PMCPMC13150796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.